1a |
Indicate the study’s design in the title/abstract |
0 (0.0) |
15 (25.0) |
45 (75.0) |
1b |
Provide in the abstract an informative and balanced summary |
0 (0.0) |
3 (5.0) |
57 (95.0) |
Introduction |
|
|
|
2 |
Explain the scientific background and rationale for the investigation |
0 (0.0) |
0 (0.0) |
60 (100.0) |
3 |
State specific objectives, including any pre-specified hypotheses |
0 (0.0) |
1 (1.7) |
59 (98.3) |
Methods |
|
|
|
|
4 |
Present key elements of study design early in the paper |
0 (0.0) |
21 (35.0) |
39 (65.0) |
5 |
Describe locations |
0 (0.0) |
2 (3.3) |
58 (96.7) |
5 |
Describe recruitment dates |
0 (0.0) |
2 (3.3) |
58 (96.7) |
5 |
Describe periods of follow-up |
0 (0.0) |
4 (6.7) |
56 (93.3) |
6a |
Give the eligibility criteria |
0 (0.0) |
4 (6.7) |
56 (93.3) |
6a |
Describe the methods of follow-up |
0 (0.0) |
2 (3.3) |
58 (96.7) |
6b |
Give matching criteria |
54 (90.0) |
0 (0.0) |
6 (10.0) |
6b |
Give number of exposed and unexposed in matched studies |
52 (86.7) |
5 (8.3) |
3 (5.0) |
7 |
Clearly define all outcomes |
0 (0.0) |
0 (0.0) |
60 (100.0) |
7 |
Clearly define all exposures |
0 (0.0) |
6 (10.0) |
54 (90.0) |
7 |
Clearly define all predictors |
0 (0.0) |
2 (3.3) |
58 (96.7) |
7 |
Clearly define all potential confounders |
0 (0.0) |
9 (15.0) |
51 (85.0) |
7 |
Clearly define all effect modifiers |
0 (0.0) |
41 (68.3) |
19 (31.7) |
8 |
Give sources of data |
0 (0.0) |
0 (0.0) |
60 (100.0) |
8 |
Method of measurement |
0 (0.0) |
1 (1.7) |
59 (98.3) |
9 |
Describe any efforts to address potential sources of bias |
0 (0.0) |
51 (85.0) |
9 (15.0) |
10 |
Explain how the study size was arrived at |
33 (55.0) |
15 (25.0) |
12 (20.0) |
11 |
Describe which groupings were chosen (if applicable) |
10 (16.7) |
8 (13.3) |
42 (70.0) |
12a |
Describe all statistical methods |
0 (0.0) |
0 (0.0) |
60 (100.0) |
12a |
Describe all statistical software |
0 (0.0) |
14 (23.3) |
46 (76.7) |
12b |
Describe any methods used to examine subgroups and interaction |
0 (0.0) |
42 (70.0) |
18 (30.0) |
12c |
Explain how missing data were addressed |
0 (0.0) |
33 (55.0) |
27 (45.0) |
12d |
explain how loss to follow-up was addressed |
3 (5.0) |
42 (70.0) |
15 (25.0) |
12e |
Describe any sensitivity analyses |
3 (5.0) |
44 (73.3) |
0 (21.7) |
Results |
|
|
|
|
13a |
Report numbers of individuals at each stage of study |
5 (8.3) |
29 (48.4) |
26 (43.3) |
13b |
Give reasons for non-participation at each stage |
5 (8.3) |
42 (70.0) |
13 (21.7) |
13c |
Consider use of a flow diagram |
0 (0.0) |
51 (85.0) |
9 (15.0) |
14a |
Give characteristics of study participants |
0 (0.0) |
5 (8.3) |
55 (81.7) |
14b |
Indicate the number of participants with missing data |
4 (6.7) |
37 (61.6) |
19 (31.7) |
14c |
Summarize follow-up time |
2 (3.3) |
32 (53.4) |
26 (43.3) |
15 |
Report numbers of outcome events or summary measures |
0 (0.0) |
0 (0.0) |
60 (100.0) |
16a |
Give unadjusted estimates |
0 (0.0) |
23 (38.3) |
37 (61.7) |
16a |
Give confounder-adjusted estimates |
1 (1.7) |
6 (10.0) |
53 (88.3) |
16a |
Give estimates precision/confidence interval |
0 (0.0) |
2 (3.3) |
58 (96.7) |
16b |
Report category boundaries when continuous variables were categorized |
8 (13.3) |
7 (11.7) |
45 (75.0) |
16c |
Consider translating estimates of relative risk into absolute risk (If relevant) |
21 (35.0) |
32 (53.3) |
7 (11.7) |
17 |
Report other analyses done e.g., subgroups analysis and sensitivity analyses |
0 (0.0) |
19 (31.7) |
41 (68.3) |
Discussion |
|
|
|
|
18 |
Summarize key results with reference to study objectives |
0 (0.0) |
0 (0.0) |
60 (100.0) |
19 |
Discuss limitations of the study |
0 (0.0) |
0 (0.0) |
60 (100.0) |
20 |
Give a cautious interpretation of results considering objectives |
0 (0.0) |
0 (0.0) |
60 (100.0) |
20 |
Explain results from similar studies |
0 (0.0) |
0 (0.0) |
60 (100.0) |
21 |
Discuss the generalizability of the study results |
0 (0.0) |
6 (10.0) |
54 (90.0) |
Other information |
|
|
|
22 |
Give the source of funding and the role of the funders |
0 (0.0) |
1 (1.7) |
59 (98.3) |
1-22 |
Total |
(7.1) |
(23.6) |
(69.3) |